News
BETRF
0.210
+19.25%
0.034
Weekly Report: what happened at BETRF last week (0720-0724)?
Weekly Report · 4d ago
Weekly Report: what happened at BETRF last week (0713-0717)?
Weekly Report · 07/20 10:27
BetterLife Pharma shifts lead drug BETR-001 development focus to migraine, headache disorders
PUBT · 07/13 18:40
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
Newsfile · 07/13 12:00
Weekly Report: what happened at BETRF last week (0706-0710)?
Weekly Report · 07/13 10:29
BetterLife Pharma appoints John W. LaRocca to board, audit committee
PUBT · 07/09 12:03
BetterLife Pharma partners with Nucro-Technics for final GLP tox study supporting BETR-001 IND filing
PUBT · 07/06 12:18
BetterLife Pharma signs deal with Nucro-Technics for final GLP tox study of BETR-001 ahead of IND filing
PUBT · 07/06 12:02
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
Newsfile · 07/06 12:00
Weekly Report: what happened at BETRF last week (0629-0703)?
Weekly Report · 07/06 10:33
Weekly Report: what happened at BETRF last week (0622-0626)?
Weekly Report · 06/29 10:28
BetterLife Pharma closes private placement raising $499,600 at $0.07 per unit
PUBT · 06/25 19:28
BetterLife Pharma extends 12.6 million warrants, including $0.10 debenture-conversion warrants, by one year
PUBT · 06/25 19:20
BetterLife Pharma names Doug Drysdale executive chairman, director
PUBT · 06/25 19:20
BetterLife Pharma hires Syner-G to oversee GMP manufacturing of BETR-001 for IND, Phase 1
PUBT · 06/25 19:14
BetterLife corrects exercise price on 3,250,000 stock options to $0.07
PUBT · 06/25 18:29
BetterLife Pharma partners with Syner-G BioPharma to oversee GMP manufacturing of BETR-001 for IND, Phase 1
PUBT · 06/25 12:16
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Newsfile · 06/25 12:00
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
Newsfile · 06/22 12:00
Weekly Report: what happened at BETRF last week (0615-0619)?
Weekly Report · 06/22 10:39
More
Webull provides a variety of real-time BETRF stock news. You can receive the latest news about Betterlife Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About BETRF
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical, is a non-hallucinogenic second-generation lysergic acid diethylamide (LSD) derivative molecule that mimics the projected therapeutic potential of LSD in the treatment of disorders, such as depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical, is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound, with the potential for treatment of anxiety related disorders, including benzodiazepine dependency. It is also refining and developing drug candidates from a set of complementary interferon-based technologies, which have the potential to engage the immune system to fight viral infections.